These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27909769)

  • 1. Evaluation of
    Gonzalez Carvalho JM; Görlich D; Schober O; Wenning C; Riemann B; Verburg FA; Vrachimis A
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):744-756. PubMed ID: 27909769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
    Danilovic DLS; Coura-Filho GB; Recchia GM; Castroneves LA; Marui S; Buchpiguel CA; Hoff AO; Kopp P
    Endocr Relat Cancer; 2022 Aug; 29(8):475-483. PubMed ID: 35613335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients.
    Garcia Alves-Junior PA; de Andrade Barreto MC; de Andrade FA; Bulzico DA; Corbo R; Vaisman F
    Endocrine; 2024 Jun; 84(3):1081-1087. PubMed ID: 38296913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
    Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
    Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer.
    de Meer SG; Vriens MR; Zelissen PM; Borel Rinkes IH; de Keizer B
    J Nucl Med; 2011 Jan; 52(1):56-9. PubMed ID: 21149483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
    Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
    Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of post-therapeutic ¹³¹I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma.
    Shen CT; Wei WJ; Qiu ZL; Song HJ; Luo QY
    Endocrine; 2016 Feb; 51(2):283-90. PubMed ID: 26093847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
    Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
    PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic differentiated thyroid cancer with negative serum stimulated Tg but positive post-therapeutic
    Li X; Li H; Yan Y; Xu H; Wang Y; Liu Y; Gao R
    Endocrine; 2023 Oct; 82(1):117-125. PubMed ID: 37209260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of treatment response to ¹³¹I therapy by diffuse hepatic uptake intensity on post-therapy whole-body scan in patients with distant metastases of differentiated thyroid cancer.
    Jun S; Lee JJ; Park SH; Kim TY; Kim WB; Shong YK; Ryu JS
    Ann Nucl Med; 2015 Aug; 29(7):603-12. PubMed ID: 25980591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulated high serum thyroglobulin with negative whole body imaging do not warrant an aggressive diagnostic and therapeutic approach in differentiated thyroid cancer patients: A follow-up of 5 years or till recurrence.
    Gupta M; Choudhury PS; Nag S; Gupta P
    Hell J Nucl Med; 2015; 18(3):207-14. PubMed ID: 26574692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.